Fig. 4: Assessment of the prognostic significance of blood-based detection of IDH1.R132H across glioma subtypes using the mt-IDH1dx assay.
From: Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas
a Kaplan–Meier analysis performed among IDH1 mutant patients using EV RNA IDH1.R132H MAF % cut-off determined by plasma testing. b Scatter-dot plot (each data point represents an individual patient; mean of eight technical replicates) demonstrating the overall distribution (mean ± SEM, denoted by horizontal line and error bars) of EV RNA IDH1.R132H MAF % across the three IDH1.R132H mutant glioma subtypes: Astrocytoma, Grade 2, 3 (n = 46, biological replicates), Oligodendroglioma, Grade 2, 3 (n = 19, biological replicates) and Astrocytoma, Grade 4 (n = 15, biological replicates). c–f Kaplan–Meier curves were evaluated among patients with IDH1 mutant glioma using different approaches: (c) patient stratification by histological diagnosis, (d–f) EV RNA IDH1.R132H MAF% cut-off unique to each subtype (d; Grade 2, Astrocytoma, e; Grade 2–3, Oligodendroglioma, f; Grade 4, Astrocytoma). P-value was calculated using Log-Rank test. Source Data are provided as a Source Data file.
